Pharmaceutical Industry Reports Myeloproliferative Neoplasms Treatment Market | Page 3

REPORT DESCRIPTION
Myeloproliferative Neoplasms Treatment Market Taxonomy:
Myeloproliferative neoplasm can significantly affect the quality of life of the patient. The
complication and treatments as well as the physiological strains of cancer diagnosis can affect
the physical and emotional wellbeing of patients. Effects of complication vary from depression,
fatigue, pain or depression with suicidal ideation. Moreover, patients can experience few or no
symptoms for a longer period of time. MPNs can be cured with proper monitoring and
treatment. There has been a major revolution in the management of MPNs by introduction of
JAK1 and JAK2 inhibitor and ruxolitinib. Ruxolitinib inhibits these two enzymes in order to
manage MPNs. The drug has also been proven as an alternative therapy for the treatment of
polycythemia vera. Further, the therapeutic armamentarium for MPN is still inadequate for
normalization of life span, reduction in cardiovascular complications, and prevention of
hematological progression.
Request for sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/930
© Coherent market Insights. All Rights Reserved